ArticleInternational urology and nephrology2026
Dynamic changes in FGF-21 and their association with inflammation and pulmonary function in ESRD patients undergoing peritoneal dialysis: a prospective cohort study.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundEnd-stage renal disease (ESRD) is frequently accompanied by systemic inflammation and pulmonary dysfunction. Fibroblast growth factor-21 (FGF-21), an emerging metabolic and inflammatory biomarker, may be involved in these pathological processes. This study aimed to evaluate dynamic changes in FGF-21 and their association with inflammatory markers-including C-reactive protein (CRP) and interleukin-6 (IL-6)-as well as pulmonary function in ESRD patients receiving peritoneal dialysis (PD).
methodsIn this prospective cohort study, 150 ESRD patients initiating PD were enrolled. Serum FGF-21, CRP, and IL-6 levels were measured at baseline and at 1, 3, and 6 months after PD initiation. Pulmonary function parameters, including forced expiratory volume in one second (FEV
resultsOver 6 months of PD, FGF-21, CRP, and IL-6 levels significantly decreased (p < 0.01). Mixed-effects linear time models demonstrated a significant decline in FGF-21 (Estimate = - 0.0457, p < 0.001), which remained significant after adjusting for residual renal function, dialysis adequacy (Kt/V), BMI, and smoking status (p < 0.001). Pulmonary function improved, with FEV₁ increasing by 0.098 L (p < 0.001), FVC by 0.101 L (p < 0.001), and DL
conclusionFGF-21 demonstrates consistent associations with inflammatory markers including CRP and IL-6, and inversely relates to pulmonary function in ESRD patients undergoing PD. These findings support the potential role of FGF-21 as an integrative biomarker for systemic inflammation, renal impairment, and respiratory dysfunction in this population.
Indexed as
Identifiers
42141316What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.